The role of alectinib in the treatment of advanced ALK-rearranged non-small-cell lung cancer
出版年份 2016 全文链接
标题
The role of alectinib in the treatment of advanced ALK-rearranged non-small-cell lung cancer
作者
关键词
-
出版物
Expert Review of Anticancer Therapy
Volume 16, Issue 12, Pages 1227-1233
出版商
Informa UK Limited
发表日期
2016-10-17
DOI
10.1080/14737140.2016.1249857
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Non–Small Cell Lung Cancer
- (2017) David S. Ettinger et al. Journal of the National Comprehensive Cancer Network
- ALK-rearranged renal cell carcinomas in children
- (2016) Mariana M. Cajaiba et al. GENES CHROMOSOMES & CANCER
- Advances in the clinicopathological and molecular classification of cutaneous mesenchymal neoplasms
- (2016) Danielle C Costigan et al. HISTOPATHOLOGY
- Multicenter Phase II Study of Whole-Body and Intracranial Activity With Ceritinib in Patients WithALK-Rearranged Non–Small-Cell Lung Cancer Previously Treated With Chemotherapy and Crizotinib: Results From ASCEND-2
- (2016) Lucio Crinò et al. JOURNAL OF CLINICAL ONCOLOGY
- Alectinib in Crizotinib-Refractory ALK-Rearranged Non–Small-Cell Lung Cancer: A Phase II Global Study
- (2016) Sai-Hong Ignatius Ou et al. JOURNAL OF CLINICAL ONCOLOGY
- Activity and safety of ceritinib in patients with ALK -rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial
- (2016) Dong-Wan Kim et al. LANCET ONCOLOGY
- Alectinib in ALK -positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial
- (2016) Alice T Shaw et al. LANCET ONCOLOGY
- ALK rearrangement testing and treatment patterns for patients with ALK-positive non-small cell lung cancer
- (2015) Annie Guérin et al. Cancer Epidemiology
- Treatment of ALK-Rearranged Non-Small Cell Lung Cancer: Recent Progress and Future Directions
- (2015) Laird Cameron et al. DRUGS
- Pharmacokinetics of crizotinib in NSCLC patients
- (2015) Gerhard Hamilton et al. Expert Opinion on Drug Metabolism & Toxicology
- Comparison of Methods in the Detection of ALK and ROS1 Rearrangements in Lung Cancer
- (2015) Toni-Maree Rogers et al. Journal of Thoracic Oncology
- Multi-institutional Oncogenic Driver Mutation Analysis in Lung Adenocarcinoma: The Lung Cancer Mutation Consortium Experience
- (2015) Lynette M. Sholl et al. Journal of Thoracic Oncology
- Future options for ALK-positive non-small cell lung cancer
- (2015) Daniela Iacono et al. LUNG CANCER
- Anaplastic Lymphoma Kinase Rearrangement in Digestive Tract Cancer: Implication for Targeted Therapy in Chinese Population
- (2015) Jianming Ying et al. PLoS One
- Novel targeted therapies for resistant ALK-rearranged non-small-cell lung cancer: ceritinib and beyond
- (2015) Cesar A. Perez et al. OncoTargets and Therapy
- Treating patients with ALK-positive non-small cell lung cancer: latest evidence and management strategy
- (2015) Bin-Chi Liao et al. Therapeutic Advances in Medical Oncology
- Alectinib: a novel second generation anaplastic lymphoma kinase (ALK) inhibitor for overcoming clinically-acquired resistance
- (2015) Zilan Song et al. Acta Pharmaceutica Sinica B
- Antitumor activity of the selective ALK inhibitor alectinib in models of intracranial metastases
- (2014) Tatsushi Kodama et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Selective ALK inhibitor alectinib with potent antitumor activity in models of crizotinib resistance
- (2014) Tatsushi Kodama et al. CANCER LETTERS
- Two Novel ALK Mutations Mediate Acquired Resistance to the Next-Generation ALK Inhibitor Alectinib
- (2014) R. Katayama et al. CLINICAL CANCER RESEARCH
- Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study
- (2014) Shirish M Gadgeel et al. LANCET ONCOLOGY
- Rationale for co-targeting IGF-1R and ALK in ALK fusion–positive lung cancer
- (2014) Christine M Lovly et al. NATURE MEDICINE
- First-Line Crizotinib versus Chemotherapy in ALK-Positive Lung Cancer
- (2014) Benjamin J. Solomon et al. NEW ENGLAND JOURNAL OF MEDICINE
- The ALK Inhibitor Ceritinib Overcomes Crizotinib Resistance in Non-Small Cell Lung Cancer
- (2014) L. Friboulet et al. Cancer Discovery
- ALK Rearrangements Are Mutually Exclusive with Mutations in EGFR or KRAS: An Analysis of 1,683 Patients with Non-Small Cell Lung Cancer
- (2013) J. F. Gainor et al. CLINICAL CANCER RESEARCH
- Detection of Circulating Tumor Cells Harboring a Unique ALK Rearrangement in ALK-Positive Non–Small-Cell Lung Cancer
- (2013) Emma Pailler et al. JOURNAL OF CLINICAL ONCOLOGY
- Identification of Somatic Genomic Alterations in Circulating Tumors Cells: Another Step Forward in Non–Small-Cell Lung Cancer?
- (2013) Daniel B. Costa JOURNAL OF CLINICAL ONCOLOGY
- Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors: Guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology
- (2013) Neal I. Lindeman et al. Journal of Thoracic Oncology
- CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1–2 study
- (2013) Takashi Seto et al. LANCET ONCOLOGY
- Testing for ALK rearrangement in lung adenocarcinoma: a multicenter comparison of immunohistochemistry and fluorescent in situ hybridization
- (2013) Christina I Selinger et al. MODERN PATHOLOGY
- Crizotinib versus Chemotherapy in Advanced ALK-Positive Lung Cancer
- (2013) Alice T. Shaw et al. NEW ENGLAND JOURNAL OF MEDICINE
- Mechanisms of Resistance to Crizotinib in Patients withALKGene Rearranged Non–Small Cell Lung Cancer
- (2012) Robert C. Doebele et al. CLINICAL CANCER RESEARCH
- Local Ablative Therapy of Oligoprogressive Disease Prolongs Disease Control by Tyrosine Kinase Inhibitors in Oncogene-Addicted Non–Small-Cell Lung Cancer
- (2012) Andrew J. Weickhardt et al. Journal of Thoracic Oncology
- Mechanisms of Acquired Crizotinib Resistance in ALK-Rearranged Lung Cancers
- (2012) R. Katayama et al. Science Translational Medicine
- Comprehensive Histologic Analysis of ALK-Rearranged Lung Carcinomas
- (2011) Akihiko Yoshida et al. AMERICAN JOURNAL OF SURGICAL PATHOLOGY
- CH5424802, a Selective ALK Inhibitor Capable of Blocking the Resistant Gatekeeper Mutant
- (2011) Hiroshi Sakamoto et al. CANCER CELL
- A Novel ALK Secondary Mutation and EGFR Signaling Cause Resistance to ALK Kinase Inhibitors
- (2011) T. Sasaki et al. CANCER RESEARCH
- CSF Concentration of the Anaplastic Lymphoma Kinase Inhibitor Crizotinib
- (2011) Daniel B. Costa et al. JOURNAL OF CLINICAL ONCOLOGY
- Targeting Oncogenic ALK: A Promising Strategy for Cancer Treatment
- (2011) E. Grande et al. MOLECULAR CANCER THERAPEUTICS
- EML4-ALK Mutations in Lung Cancer That Confer Resistance to ALK Inhibitors
- (2010) Young Lim Choi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
- (2010) Eunice L. Kwak et al. NEW ENGLAND JOURNAL OF MEDICINE
- Clinical Features and Outcome of Patients With Non–Small-Cell Lung Cancer Who Harbor EML4-ALK
- (2009) Alice T. Shaw et al. JOURNAL OF CLINICAL ONCOLOGY
- EML4-ALK Fusion Is Linked to Histological Characteristics in a Subset of Lung Cancers
- (2008) Kentaro Inamura et al. Journal of Thoracic Oncology
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started